Wegovy® Delivered Substantial Weight Loss In Women Across All Menopause Stages, Plus Heart And Migraine Protection, Shown In New Novo Nordisk Data At The European Congress On Obesity

(MENAFN- Mid-East Info) Dubai, May 2026 – Novo Nordisk today announced data demonstrating that Wegovy® (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond1. The menopausal stages are perimenopause (the transition phase), menopause and postmenopause (after menopause).

The findings are based on the STEP UP clinical weight management trial, the landmark SELECT clinical cardiovascular trial and one large-scale real-world evidence study, all presented at the European Congress on Obesity (ECO) 2026 in Istanbul, Turkey1-3. The studies show that when women with obesity lose weight with semaglutide, they improve their body composition with reduced waist circumference, indicative of less visceral fat, and they also reduce their risk of heart attacks and strokes while improving their quality of life, from migraine burden to depression and menopause symptoms1-3.

Nearly one in five women worldwide are now living with obesity, and the burden intensifies during the menopause years, when hormonal changes drive weight gain, redistribute fat to the abdomen, and increase cardiometabolic risk4-6. During menopause years, women's risk of heart attack rises notably and to the same level of men's cardiovascular risk7-9. Cardiovascular disease remains the leading cause of death in women worldwide, claiming more lives than all cancers combined10. Yet women's cardiovascular symptoms are frequently dismissed or misdiagnosed, and women remain underrepresented in heart disease research7.

“For women with obesity, hormonal changes during menopause can drive weight gain and increase the risk of a heart attack,” said Mette Thomsen, group vice president and head of Global Medical Affairs at Novo Nordisk.“New clinical and real-world data presented at ECO demonstrate that effective weight management with semaglutide around menopause addresses medical complications of obesity, such as heart disease and metabolic dysfunction. But it can also help address daily burdens such as migraine, depression and menopause-related challenges. We are excited to share new insights that may benefit the many women living with obesity.”

MENAFN12052026005446012082ID1111101138